Request a Quote |

Cyprotex Highlights - February 2021


We recently announced the latest edition of Evotec’s Drug Discovery Update (DDup). This edition is dedicated to our next generation transcriptomics toxicology platform, a truly translational project across different groups at Evotec.

The development of this platform has been a combined effort of toxicology experts, bioinformaticians and transcriptomics specialists leading to one of our latest offerings, a unique end-to-end in vitro toxicology transcriptomics service that can be customised according to customer’s needs.

Find out more by downloading the publication:

Download the publication

Or contact us to discuss our toxicology transcriptomics platform:

Enquire about the service

Transcriptomics Research

From March 12-26 2021, Cyprotex and parent company, Evotec, will be exhibiting at the Annual Society of Toxicology Meeting (SOT). At this virtual event you can find us at booth number 1941 (Cyprotex) and 2040 (Evotec).

Our panel of experts will be on hand to discuss your project and keep you up-to-date on our latest research. You can request a virtual meeting with them by contacting us:

Arrange a meeting

We also have a full schedule of presentations and posters to share with you over the course of the event including an exhibitor hosted session; find out more using the link below:

Learn more

Presenting at SOT

We recently added the mitochondrial oxidative stress assay to our toxicology portfolio.

The assay detects selective mitochondrial reactive oxygen species (mROS) production caused by the toxicity of novel compounds. Find out more by visiting the assay page:

Visit the assay page

Enquire about the service

Early stage key decisions in drug discovery strongly influence overall development cost, time and the probability of delivering a successful new medicine.

In this webinar series, scientific experts will present on Evotec's differentiated approach to drug discovery and development by considering it as a continuum rather than discrete hand-over between traditionally separate departments. This integrated approach has enabled invention and selection of the highest quality molecules leading to improved success rates during preclinical development candidate nomination and clinical development.

Register for the webinar series

Read the latest news from parent company, Evotec:

  • Evotec achieves milestone in iPSC-based neuroscience partnership with Bristol Myers Squibb
  • Just-Evotec Biologics expands agreement with the DoD for production of monoclonal antibodies
  • Evotec, NIAID and Duke Clinical Research Institute begins clinical development of chikungunya antibody
  • Evotec announces CSO Dr Cord Dohrmann has been appointed to the German Council of Science and Humanities
  • Evotec announces a multi-year partnership with the Medical Center Hamburg-Eppendorf to develop iPSC-based tissue therapy for heart failure
  • Evotec begin partnership with Related Sciences for integrated drug discovery and development

Read the press releases

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: